{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:35:33Z","timestamp":1761921333132,"version":"3.41.2"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272855","81972453","81972597"],"award-info":[{"award-number":["82272855","81972453","81972597"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Provincial Natural Science Foundation of China","award":["LR22H160011","LY19H160055","LY19H160059","LY18H160005","LY20H160026"],"award-info":[{"award-number":["LR22H160011","LY19H160055","LY19H160059","LY18H160005","LY20H160026"]}]},{"name":"Zhejiang Provincial Medical and Health Science and Technology","award":["2021RC016"],"award-info":[{"award-number":["2021RC016"]}]},{"name":"Zheng Shu Medical Elite Scholarship Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The impact of concurrent proton pump inhibitors (PPIs) use on the prognosis of patients with breast cancer undergoing cyclin-dependent kinase inhibitors (CDKIs) treatment is currently uncertain. Considerable divergence exists regarding the clinical studies. In this study, we aim to perform a comprehensive analysis to evaluate the influence of concomitant PPI use on the effectiveness and adverse effects of CDKIs in patients with breast cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study encompassed all pertinent clinical studies published up to the present, following the PRISMA guidelines. The study used hazard ratio (HR) or odds ratio (OR) as a summary statistic and used fixed or random effects models for pooled estimation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>This study incorporated 10 research articles involving 2993 participants. Among patients with breast cancer undergoing treatment with CDKIs, the simultaneous administration of PPIs was associated with a notable reduction in overall survival (HR\u2005=\u20052.00; 95% CI, 1.35-2.96). Nevertheless, no substantial correlation was observed between the simultaneous utilization of PPIs and the progression-free survival (PFS) of patients (HR\u2005=\u20051.30; 95% CI, 0.98-1.74). PFS did not change significantly when considering different drugs, treatment lines, or regions alone. Furthermore, the simultaneous administration of PPIs was found to result in a notable decrease in the incidence of grades 3\/4 risk factors (OR\u2005=\u20050.63, 95% CI, 0.46-0.85).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The concurrent administration of PPIs did not result in significant alterations in the risk of disease advancement among patients with breast cancer undergoing CDKIs treatment. The utilization of PPIs led to a decrease in the adverse effects linked to the administration of CDKIs.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyae320","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T09:43:36Z","timestamp":1739871816000},"source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of cyclin-dependent kinase inhibitors with concurrent proton pump inhibitors in patients with breast cancer: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"30","author":[{"given":"Zijie","family":"Guo","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine , Hangzhou, Zhejiang 310016 ,","place":["People\u2019s Republic of China"]},{"name":"Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province , Hangzhou, Zhejiang 310016 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine , Hangzhou, Zhejiang 310016 ,","place":["People\u2019s Republic of China"]},{"name":"Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province , Hangzhou, Zhejiang 310016 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingpeng","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine , Hangzhou, Zhejiang 310016 ,","place":["People\u2019s Republic of China"]},{"name":"Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province , Hangzhou, Zhejiang 310016 ,","place":["People\u2019s Republic of China"]},{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University , Hangzhou, Zhejiang 310014 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yijia","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine , Hangzhou, Zhejiang 310016 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xixi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine , Hangzhou, Zhejiang 310016 ,","place":["People\u2019s Republic of China"]},{"name":"Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province , Hangzhou, Zhejiang 310016 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingliang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine , Hangzhou, Zhejiang 310016 ,","place":["People\u2019s Republic of China"]},{"name":"Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province , Hangzhou, Zhejiang 310016 ,","place":["People\u2019s Republic of China"]},{"name":"The Ninth People\u2019s Hospital of Hangzhou , Hangzhou, Zhejiang 310014 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenkangle","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine , Hangzhou, Zhejiang 310016 ,","place":["People\u2019s Republic of China"]},{"name":"Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province , Hangzhou, Zhejiang 310016 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linbo","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine , Hangzhou, Zhejiang 310016 ,","place":["People\u2019s Republic of China"]},{"name":"Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province , Hangzhou, Zhejiang 310016 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0727-4034","authenticated-orcid":false,"given":"Jichun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Affiliated Sir Run Run Shaw Hospital, Zhejiang University School of Medicine , Hangzhou, Zhejiang 310016 ,","place":["People\u2019s Republic of China"]},{"name":"Biomedical Research Center and Key Laboratory of Biotherapy of Zhejiang Province , Hangzhou, Zhejiang 310016 ,","place":["People\u2019s Republic of China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,2,18]]},"reference":[{"key":"2025030422473778700_CIT0001","doi-asserted-by":"publisher","first-page":"20211033","DOI":"10.1259\/bjr.20211033","article-title":"Understanding breast cancer as a global health concern","volume":"95","author":"Wilkinson","year":"2022","journal-title":"Br J Radiol"},{"key":"2025030422473778700_CIT0002","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet (London, England)"},{"key":"2025030422473778700_CIT0003","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"2025030422473778700_CIT0004","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40265-020-01461-2","article-title":"Inhibiting CDK4\/6 in breast cancer with palbociclib, ribociclib, and abemaciclib: similarities and differences","volume":"81","author":"Braal","year":"2021","journal-title":"Drugs"},{"key":"2025030422473778700_CIT0005","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","article-title":"The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment","volume":"21","author":"Morrison","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"2025030422473778700_CIT0006","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"key":"2025030422473778700_CIT0007","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"2025030422473778700_CIT0008","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1505270","article-title":"Palbociclib in hormone-receptor-positive advanced breast cancer","volume":"373","author":"Turner","year":"2015","journal-title":"N Engl J Med"},{"key":"2025030422473778700_CIT0009","doi-asserted-by":"publisher","first-page":"27","DOI":"10.5009\/gnl15502","article-title":"25 years of proton pump inhibitors: a comprehensive review","volume":"11","author":"Strand","year":"2017","journal-title":"Gut Liver"},{"key":"2025030422473778700_CIT0010","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1158\/1078-0432.CCR-18-2748","article-title":"Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated within the EORTC 62043\/62072 trials","volume":"25","author":"Mir","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025030422473778700_CIT0011","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41416-021-01606-4","article-title":"Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150","volume":"126","author":"Hopkins","year":"2022","journal-title":"Br J Cancer"},{"key":"2025030422473778700_CIT0012","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bcpt.13023","article-title":"Side effects of long-term proton pump inhibitor use: a review","volume":"123","author":"Haastrup","year":"2018","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"2025030422473778700_CIT0013","doi-asserted-by":"publisher","first-page":"100231","DOI":"10.1016\/j.esmoop.2021.100231","article-title":"Drug-drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of metastatic breast cancer patients","volume":"6","author":"Del Re","year":"2021","journal-title":"ESMO Open"},{"key":"2025030422473778700_CIT0014","doi-asserted-by":"publisher","first-page":"5133","DOI":"10.3390\/cancers15215133","article-title":"The association between proton pump inhibitors and the effectiveness of CDK inhibitors in HR+\/HER- advanced breast cancer patients: a systematic review and meta-analysis","volume":"15","author":"Chang","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025030422473778700_CIT0015","doi-asserted-by":"publisher","first-page":"1352224","DOI":"10.3389\/fphar.2024.1352224","article-title":"Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4\/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis","volume":"15","author":"de Moraes","year":"2024","journal-title":"Front Pharmacol"},{"key":"2025030422473778700_CIT0016","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.esmoop.2023.101431","article-title":"243P concomitant administration of palbociclib and proton pump inhibitors affects clinical outcomes in metastatic breast cancer patients","volume":"8","author":"Criado","year":"2023","journal-title":"ESMO Open"},{"key":"2025030422473778700_CIT0017","doi-asserted-by":"publisher","first-page":"e741","DOI":"10.1093\/oncolo\/oyae015","article-title":"Proton pump inhibitors and cyclin-dependent kinase 4\/6 inhibitors in patients with breast cancer","volume":"29","author":"Takahashi","year":"2024","journal-title":"Oncologist"},{"key":"2025030422473778700_CIT0018","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1590\/S1677-5538.IBJU.2017.03.02","article-title":"PRISMA statement and PROSPERO","volume":"43","author":"Bernardo","year":"2017","journal-title":"Int Braz J Urol"},{"key":"2025030422473778700_CIT0019","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg (London, England)"},{"key":"2025030422473778700_CIT0020","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"2025030422473778700_CIT0021","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clin Res Ed)"},{"key":"2025030422473778700_CIT0022","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ (Clin Res Ed)"},{"key":"2025030422473778700_CIT0023","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"2025030422473778700_CIT0024","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2025030422473778700_CIT0025","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clin Res Ed)"},{"key":"2025030422473778700_CIT0026","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.breast.2022.10.005","article-title":"Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib","volume":"66","author":"Del Re","year":"2022","journal-title":"Breast"},{"key":"2025030422473778700_CIT0027","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s12885-022-09624-y","article-title":"Proton pump inhibitors may reduce the efficacy of ribociclib and palbociclib in metastatic breast cancer patients based on an observational study","volume":"22","author":"Eser","year":"2022","journal-title":"BMC Cancer"},{"key":"2025030422473778700_CIT0028","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s00228-022-03435-7","article-title":"The effect of concomitant use of proton pump inhibitors with CDK 4\/6 inhibitors on survival in metastatic breast cancer","volume":"79","author":"Caglayan","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"2025030422473778700_CIT0029","doi-asserted-by":"publisher","first-page":"PD13","DOI":"10.1158\/1538-7445.sabcs22-pd13-10","article-title":"Abstract PD13-10: PD13-10 impact of proton pump inhibitors (PPI) on palbociclib (PAL) outcomes in hormone receptor-positive, HER2-negative advanced breast cancer (HR+\/HER2-ABC): exploratory analysis of the PARSIFAL trial","volume":"83","author":"Cosimo","year":"2023"},{"key":"2025030422473778700_CIT0030","doi-asserted-by":"publisher","first-page":"e2324852","DOI":"10.1001\/jamanetworkopen.2023.24852","article-title":"Concomitant use of proton pump inhibitors and palbociclib among patients with breast cancer","volume":"6","author":"Lee","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025030422473778700_CIT0031","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3390\/medicina59030557","article-title":"Does proton pump inhibitors decrease the efficacy of palbociclib and ribociclib in patients with metastatic breast cancer","volume":"59","author":"Odabas","year":"2023","journal-title":"Medicina"},{"key":"2025030422473778700_CIT0032","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.clbc.2023.05.009","article-title":"Effect of concurrent proton pump inhibitors with palbociclib tablets for metastatic breast cancer","volume":"23","author":"Schieber","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"2025030422473778700_CIT0033","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1002\/cpt.940","article-title":"Ribociclib bioavailability is not affected by gastric pH changes or food intake: in silico and clinical evaluations","volume":"104","author":"Samant","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"2025030422473778700_CIT0034","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/cpdd.356","article-title":"Impact of acid-reducing agents on the pharmacokinetics of palbociclib, a weak base with pH-dependent solubility, with different food intake conditions","volume":"6","author":"Sun","year":"2017","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2025030422473778700_CIT0035","first-page":"1","article-title":"A phase 1, open-label, two-period, fixed-sequence study of the effect of a proton pump inhibitor on the relative bioavailability of the proposed commercial tablet formulation of palbociclib in healthy volunteers","volume":"8","author":"Yu","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2025030422473778700_CIT0036","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00210-001-0489-7","article-title":"Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein","volume":"364","author":"Pauli-Magnus","year":"2001","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2025030422473778700_CIT0037","doi-asserted-by":"publisher","first-page":"458","DOI":"10.2174\/1389200224666230815122312","article-title":"Molecular insights into the mechanism of modulatory effects of proton pump inhibitors on P-glycoprotein mediated drug transport of palbociclib and ribociclib","volume":"24","author":"Desai","year":"2023","journal-title":"Curr Drug Metab"},{"key":"2025030422473778700_CIT0038","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1053\/j.gastro.2019.07.039","article-title":"Safety and complications of long-term proton pump inhibitor therapy: getting closer to the truth","volume":"157","author":"Corley","year":"2019","journal-title":"Gastroenterology"},{"key":"2025030422473778700_CIT0039","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3390\/cancers15010284","article-title":"The association between baseline proton pump inhibitors, immune checkpoint inhibitors, and chemotherapy: a systematic review with network meta-analysis","volume":"15","author":"Chang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025030422473778700_CIT0040","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/cts.12902","article-title":"Optimizing the therapeutic window of targeted drugs in oncology: potency-guided first-in-human studies","volume":"14","author":"Goldstein","year":"2021","journal-title":"Clin Transl Sci"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/2\/oyae320\/61934858\/oyae320.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/2\/oyae320\/61934858\/oyae320.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T22:48:04Z","timestamp":1741128484000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae320\/8019836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae320","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2025,2]]},"article-number":"oyae320"}}